(April 7, 2014) A group of OCRF-funded researchers at Baylor College of Medicine have found a “fusion gene” that is present in 20% of high grade serous ovarian cancer patients. The finding, which was published in PLOS Genetics, was supported in part by OCRF grants to Martin Matzuk, MD, PhD, Shannon Hawkins, MD, PhD, and … Continued
(April 1, 2014) Ovarian Cancer Research Fund is now accepting Letters of Intent for its three research grant programs. Letters of Intent must be submitted by May 6, 2014 at 5:00pm ET.
OCRF-funded research at UC Davis have verified that glycans (sugars attached to proteins) can be used to identify ovarian cancer. The study was published online in the journal Cancer Epidemiology, Biomarkers & Prevention. “This is one of many papers we’ve done to see if glycans can distinguish between women who have ovarian cancer and those who … Continued
Program Gynecologic Cancer Patients to Receive New Support in Providence, New Orleans, Houston and The Bronx WEST CHESTER, Pa (March 10, 2014) —Ovarian Cancer Research Fund (OCRF) and QVC today announced four new Woman to Woman grant recipients: Women & Infants Hospital of Rhode Island, Providence, RI; Tulane Cancer Center, New Orleans, LA; Baylor College … Continued
FOR IMMEDIATE RELEASE: February 7, 2014 Further Study Needed Before Clinical Recommendations Change Washington, DC—A study published yesterday by the National Institutes of Health found that women who took aspirin on a daily basis had a 20 percent reduction in risk of ovarian cancer. The Ovarian Cancer National Alliance released the following statement in response … Continued
(January 30, 2014) OCRF grantee Yin Wang, PhD, led research which found that PKC iota signaling plays an important role in ovarian cancer development. The research, which was published in Molecular Cancer Research, also found that Auranofin, a small molecular compound, shows potential for treating ovarian cancer. The research study was funded in part by … Continued
FOR IMMEDIATE RELEASE: January 24, 2014 Washington, DC—In response to a recent speech by Mike Huckabee, in which he stated that women use oral contraceptives because they “cannot control their libidos or their reproductive systems,” the Ovarian Cancer National Alliance issued the following statement from CEO Calaneet Balas: “In his quest for a quotable sound … Continued
(January 13, 2014) Researchers at Case Western Reserve University, led by OCRFA grantee Analisa DiFeo, PhD have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a finding that has the potential to improve outcomes for patients with the disease. The findings were published … Continued
Kicks off 20th Anniversary with an unprecedented grant award for scientific research and gynecologic cancer patient support program New York, NY January 13, 2014 — To mark its 20th anniversary, Ovarian Cancer Research Fund has awarded a record-breaking $6.9 million in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. … Continued
OCRF has awarded $6.5 million in research grants to 22 scientists at leading medical institutions across the country.
New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued
A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers. These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued
Get email updates about research news, action alerts, and ways to join the fight.
